OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Clinical data for TLC-6740 demonstrate additive metabolic benefits in combination with tirzepatide
Novel preclinical findings for TLC-1180 demonstrate exercise-mimetic, insulin-sensitizing, and cognition-preserving effects
OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced new clinical and preclinical data to be presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8, 2026, in New Orleans, La. The findings underscore the potential multi-system benefits of the mitochondrial protonophore mechanism, with effects spanning weight loss, multi-tissue insulin sensitivity, exercise capacity, cardiovascular health, and obesity-associated cognitive decline.
OrsoBio will present clinical data from a Phase 2a study of TLC-6740 in combination with tirzepatide in people living with obesity without diabetes (NCT05822544). The randomized, double-blind, placebo-controlled study demonstrated significant improvements in weight loss, insulin sensitivity, liver health, and body composition compared with tirzepatide monotherapy. TLC-6740 was safe and well tolerated in combination with tirzepatide, consistent with prior clinical studies of TLC-6740.
